Business Wire

BITFURY-GROUP

4.11.2021 13:02:08 CET | Business Wire | Press release

Share
Bitfury Appoints Former United States Acting Comptroller of the Currency Brian P. Brooks Chief Executive Officer

Bitfury Group (“Bitfury” or the “Company”), the Bitcoin mining and crypto tech pioneer, today announced that Brian P. Brooks, former United States Acting Comptroller of the Currency, has joined the Company as Chief Executive Officer, effective October 29, 2021. Mr. Brooks will lead the 10-year-old crypto unicorn as it launches a new funding round, increases the growth of its mining business with a revolutionary new microchip design and new global data center locations, and scales a portfolio of innovative businesses that grew out of the Company’s heritage as an early Bitcoin leader. Valery Vavilov, Founder of Bitfury, will become Chairman of the Board of Directors and Chief Vision Officer, where he will continue his focus on developing over-the-horizon hardware and software innovations for Bitfury as it builds the infrastructure for a tokenized global economy.

Mr. Vavilov said, “Since our founding, Bitfury has pioneered innovative blockchain hardware and software infrastructure, and today represents a comprehensive platform addressing and enhancing the full digital asset value chain. With an eye toward the next phase in our evolution, we are thrilled to welcome Brian to the Company. Brian is a respected executive and thought leader with deep regulatory, digital asset and capital markets expertise who shares Bitfury’s vision for a decentralized peer-to peer economy. Together, we will continue to execute Bitfury’s growth strategy and help businesses, governments, organizations, and individuals leverage the blockchain to solve the most pressing challenges of today and tomorrow.”

Since its inception in 2011, Bitfury has developed into a full-service blockchain technology company and one of the world’s leading providers of large-scale digital asset infrastructure solutions. Bitfury’s platform of emerging technologies businesses includes its self-mining operations, with seven ultra-low-cost energy sites globally alongside its new United-States based Cipher Mining subsidiary; hardware products for high-performance computing needs, including seven generations of its own specialized micro-chips and next generation immersion cooling systems; and software and enterprise blockchain solutions spanning security, payments, and applications for the creator economy, among others.

Mr. Brooks said, “Bitfury is an established leader in the digital asset industry, renowned for its sustained research and development efforts and best-in-class proprietary technologies. As the adoption of – and use cases for – Bitcoin, other cryptoassets, and their underlying blockchains continues to accelerate worldwide, the Company’s diversified portfolio has immense opportunity and is well positioned for long-term success. I look forward to working alongside Valery and Bitfury’s highly experienced leadership team to grow the Company’s core businesses and scale its portfolio of new innovations.”

Brian P. Brooks Biography

Most recently, Mr. Brooks served as Chief Executive Officer of digital asset exchange and marketplace Binance.US. Previously, from May 2020 to January 2021, Mr. Brooks served as the Acting Comptroller of the Currency, where he was the administrator of the federal banking system and the chief executive of the 3,500-employee federal agency responsible for chartering and supervising banks comprising 70 percent of all banking activity in the United States. He also served as a member of the board of directors of the Federal Deposit Insurance Corporation and a voting member of the Financial Stability Oversight Council. Often referred to in the media as “the first fintech Comptroller” and “CryptoComptroller” for his work advancing financial innovation, Mr. Brooks led the government’s efforts to provide regulatory clarity for stablecoins, digital asset custody, and the development of blockchain payment networks, and granted the first federal bank charter to a cryptocurrency company. He also launched Project REACh, a national partnership of civil rights organizations, tech companies, and banks to promote financial inclusion through greater access to credit and capital.

From 2018 to 2020, Mr. Brooks served as Chief Legal Officer of Coinbase Global, Inc., where he led legal, compliance, internal audit, government relations, and global investigations groups at the digital asset platform. From 2014 to 2018, he served as Executive Vice President, General Counsel, and Corporate Secretary of Fannie Mae, a $3.2 trillion asset public company that is the world’s largest investor in single-family and multifamily mortgage assets, and from 2011 to 2014, as Vice Chairman of OneWest Bank, N.A. Before joining OneWest Bank, N.A., he served as managing partner of O’Melveny & Myers LLP’s Washington, D.C. office.

Mr. Brooks also serves as an adviser or board member for a number of financial and fintech companies. Mr. Brooks received his BA from Harvard University and his JD from the University of Chicago.

About Bitfury Group

Bitfury Group is the world's leading technology company unlocking the full value chain of Bitcoin and other digital assets. Bitfury™ has built on its heritage as one of the earliest Bitcoin miners and developers of mining equipment to create solutions for the future – solutions such as the Crystal™ Blockchain advanced analytics platform, which helps law enforcement and private sector clients make cryptoassets safer and more compliant; the Liquidstack immersion cooling business, which dramatically reduces data center energy usage and makes Bitcoin mining and high performance computing more environmentally sustainable; Axelera AI, which unlocks the potential of artificial intelligence with the world’s most advanced AI technologies; Surround, providing blockchain-based solutions for the creator economy including digital rights management, payments, and NFT support; and others. Our mission is to make the world more secure and trusted by innovating at every level of technology – hardware, security, and software – to put trust back into the equation. To learn more, visit www.bitfury.com .

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye